查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1956821

细胞及基因治疗製造服务市场分析及预测（至2035年）：类型、产品类型、服务、技术、组件、应用、製程、最终用户、阶段

Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 330 Pages | 商品交期: 3-5个工作天内

价格
简介目录

细胞和基因治疗生产服务市场预计将从2024年的148亿美元成长到2034年的517亿美元，复合年增长率约为13.6%。该市场涵盖专门从事细胞和基因治疗生产的设施和服务，包括製程开发、品管和法规遵循。推动该市场成长的因素包括个人化医疗的进步、对创新治疗方法日益增长的需求以及对专业生产能力的需求。为了满足对复杂生物生物製药日益增长的需求，该行业高度重视扩充性、成本效益和技术创新。

细胞和基因治疗生产服务市场正经历强劲成长，这主要得益于个人化医疗和再生医学领域的创新。细胞治疗领域成长最为迅猛，自体细胞疗法凭藉其个人化治疗方案和潜在的高疗效而主导。在该领域，CAR-T细胞疗法因其在治疗某些癌症方面的成功案例而备受关注。基因疗法紧随其后，体内基因疗法也展现出良好的发展前景，其优势在于可直接给药，并有望用于治疗遗传性疾病。体外基因疗法则是第三，其特征是在细胞重新註入患者体内之前，能够精确控制基因修饰。由于生产流程外包的日益普及，专注于这些治疗方法的合约开发和生产组织（CDMO）的重要性日益凸显。市场对可扩展生产解决方案和先进生物製程技术的需求不断增长，反映出产业对效率和成本效益的迫切需求。这些趋势凸显了市场的动态发展和巨大的潜在盈利机会。

市场区隔
类型 异体移植、自体移植、病毒载体、非病毒载体、质体DNA、细胞株、基因编辑
产品 细胞治疗产品、基因治疗产品、病毒载体产品、非病毒载体产品、质体DNA产品
服务 製程开发、分析测试、品管、法规支援、供应链管理
科技 CRISPR、TALEN、ZFN、慢病毒载体、AAV载体、逆转录病毒载体
成分 试剂、培养基、缓衝液、无血清培养基
应用领域 肿瘤科、心血管疾病科、神经系统疾病科、罕见疾病科、感染疾病
流程 上游工程、下游製程、填充和精加工
最终用户 生物製药公司、研究机构、受託研究机构
步 临床前、临床和商业化生产阶段

策略定价和创新产品推出正在推动细胞和基因治疗生产服务市场市场份额的动态变化。主要企业正利用先进技术提高生产效率并实施具有竞争力的定价策略。新型治疗方法的推出正在改变整个产业，企业正专注于个人化和标靶治疗。这种演变在医疗基础设施发达的地区尤其显着，加速了对最先进治疗的需求。竞争基准分析揭示了激烈的市场竞争格局，老牌企业和新兴企业都在争夺主导。监管的影响至关重要，尤其是在北美和欧洲等地区，严格的标准正在影响企业的市场准入和扩大策略。企业正在大力投资合规和品质保证，以满足这些监管要求。市场分析强调了策略伙伴关係关係和合作的重要性，这对于驾驭复杂的监管环境和实现永续成长至关重要。

主要趋势和驱动因素：

细胞和基因治疗生产服务市场正经历强劲成长，这主要得益于几个关键趋势和驱动因素。其中一个显着趋势是人们对个人化医疗的需求日益增长，这推动了细胞和基因治疗技术的进步。这一趋势反映了治疗领域向个人化治疗的广泛转变，旨在满足个别患者的需求，从而提高治疗效果和疗效。此外，生产流程的技术进步正在革新市场。自动化系统和一次性技术等创新正在提高效率和扩充性，降低生产成本，并加快产品上市速度。这些进步对于满足日益增长的细胞和基因治疗需求至关重要。监管支持和有利的政策也在推动市场成长。各国政府和监管机构透过简化核准流程和提供研发奖励，促进该领域的创新和投资。此外，生技公司和学术机构之间的合作正在加速新型治疗方法的开发，以扩大市场潜力。最后，慢性病和遗传性疾病的日益普遍也推动了对细胞和基因疗法的需求。随着人们对这些治疗方法的认识不断提高，对可靠的生产服务的需求也随之增长，以确保这些疗法的可用性和可及性。这些因素综合起来，为市场的持续扩张奠定了基础，为相关人员提供了盈利的机会。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 同种异体移植
    • 自体移植
    • 病毒载体
    • 非病毒载体
    • 质体DNA
    • 细胞株
    • 基因编辑
  • 市场规模及预测：依产品划分
    • 细胞治疗产品
    • 基因治疗产品
    • 病毒载体产品
    • 非病毒载体产品
    • 质体DNA产物
  • 市场规模及预测：依服务划分
    • 製程开发
    • 分析测试
    • 品管
    • 监管支持
    • 供应链管理
  • 市场规模及预测：依技术划分
    • CRISPR
    • TALEN
    • ZFN
    • 慢病毒载体
    • AAV载体
    • 逆转录病毒载体
  • 市场规模及预测：依组件划分
    • 试剂
    • 媒体
    • 缓衝
    • 无血清培养基
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心血管疾病
    • 神经系统疾病
    • 罕见疾病
    • 感染疾病
  • 市场规模及预测：依製程划分
    • 上游工程
    • 下游工艺
    • 填充/包装过程
  • 市场规模及预测：依最终用户划分
    • 生物製药公司
    • 研究所
    • 合约研究机构
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • 临床
    • 商业的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Wu Xi App Tec
  • Lonza
  • Catalent
  • Sartorius
  • Thermo Fisher Scientific
  • Charles River Laboratories
  • Parexel
  • Pall Corporation
  • Bio NTech
  • Fujifilm Diosynth Biotechnologies
  • Samsung Biologics
  • AGC Biologics
  • Cognate Bio Services
  • Oxford Biomedica
  • Miltenyi Biotec
  • Cell and Gene Therapy Catapult
  • Center for Breakthrough Medicines
  • Vineti
  • Bluebird Bio
  • Orchard Therapeutics

第九章：关于我们

简介目录
Product Code: GIS21083

Cell and Gene Therapy Manufacturing Services Market is anticipated to expand from $14.8 billion in 2024 to $51.7 billion by 2034, growing at a CAGR of approximately 13.6%. The Cell and Gene Therapy Manufacturing Services Market encompasses facilities and services dedicated to the production of cell and gene therapies, including process development, quality control, and regulatory compliance. This market is driven by advancements in personalized medicine, increasing demand for innovative therapies, and the need for specialized manufacturing capabilities. The sector emphasizes scalability, cost-efficiency, and technological innovation to meet the rising demand for complex biologics.

The Cell and Gene Therapy Manufacturing Services Market is experiencing robust growth, propelled by innovations in personalized medicine and regenerative therapies. The cell therapy segment is the top performer, with autologous cell therapies leading due to their personalized approach and potential for high efficacy. Within this segment, CAR-T cell therapies are particularly noteworthy, given their success in treating certain cancers. Gene therapy follows closely, with in vivo gene therapy showing promise due to its direct delivery method and potential for treating genetic disorders. The second highest performing segment is ex vivo gene therapy, which offers precise control over genetic modifications before reintroducing cells into the patient. Contract development and manufacturing organizations (CDMOs) specializing in these therapies are gaining traction, driven by the increasing outsourcing of manufacturing processes. The demand for scalable manufacturing solutions and advanced bioprocessing technologies is rising, reflecting the industry's need for efficiency and cost-effectiveness. These trends underscore the market's dynamic evolution and potential for lucrative opportunities.

Market Segmentation
TypeAllogeneic, Autologous, Viral Vectors, Non-viral Vectors, Plasmid DNA, Cell Lines, Gene Editing
ProductCell Therapy Products, Gene Therapy Products, Viral Vector Products, Non-viral Vector Products, Plasmid DNA Products
ServicesProcess Development, Analytical Testing, Quality Control, Regulatory Support, Supply Chain Management
TechnologyCRISPR, TALEN, ZFN, Lentiviral Vectors, AAV Vectors, Retroviral Vectors
ComponentReagents, Media, Buffers, Serum-Free Media
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases, Infectious Diseases
ProcessUpstream Processing, Downstream Processing, Fill and Finish
End UserBiopharmaceutical Companies, Research Institutes, Contract Research Organizations
StagePreclinical, Clinical, Commercial

The Cell and Gene Therapy Manufacturing Services Market is witnessing a dynamic shift in market share, driven by strategic pricing and innovative product launches. Key industry players are leveraging advanced technologies to enhance manufacturing efficiencies, thereby offering competitive pricing strategies. The introduction of novel therapies is reshaping the landscape, with companies focusing on personalized medicine and targeted treatments. This evolution is particularly pronounced in regions with robust healthcare infrastructure, where demand for cutting-edge therapies is accelerating. Competition benchmarking reveals a highly competitive environment, with established firms and emerging players vying for dominance. Regulatory influences play a pivotal role, particularly in regions like North America and Europe, where stringent standards impact market entry and expansion strategies. Companies are investing heavily in compliance and quality assurance to meet these regulatory demands. The market analysis underscores the importance of strategic partnerships and collaborations, which are essential for navigating the complex regulatory landscape and achieving sustainable growth.

Geographical Overview:

The Cell and Gene Therapy Manufacturing Services Market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, propelled by advanced healthcare infrastructure and substantial investments in biotechnology. The region's strong research and development capabilities further bolster its position as a market leader. Europe follows, with significant government support and a strong focus on innovative therapies, enhancing its market potential. In the Asia Pacific, the market is expanding rapidly. This growth is driven by increasing healthcare expenditures and technological advancements in biotechnology. Countries like China and India are emerging as key players due to their large patient populations and favorable regulatory environments. Latin America and the Middle East & Africa are also showing promising growth. Latin America benefits from rising investments in healthcare infrastructure, while the Middle East & Africa are recognizing the potential of cell and gene therapies in addressing unmet medical needs.

Global tariffs and geopolitical risks are significantly influencing the Cell and Gene Therapy Manufacturing Services Market. In Japan and South Korea, trade tensions with the US and China are prompting increased investment in domestic biotech capabilities to mitigate reliance on foreign inputs. China is accelerating its push for self-sufficiency in biopharmaceuticals, while Taiwan leverages its advanced manufacturing prowess to strengthen its position as a key player. The parent market is experiencing robust growth due to rising demand for advanced therapeutics. By 2035, the market is expected to expand significantly, driven by innovation and strategic regional collaborations. Middle East conflicts could disrupt global supply chains, affecting energy prices and manufacturing costs, thereby impacting the biomanufacturing sector's growth trajectory.

Key Trends and Drivers:

The Cell and Gene Therapy Manufacturing Services Market is experiencing robust growth driven by several key trends and drivers. A significant trend is the increasing demand for personalized medicine, which is propelling advancements in cell and gene therapies. This trend reflects a broader shift towards tailored treatments that cater to individual patient needs, enhancing therapeutic efficacy and outcomes. Additionally, technological advancements in manufacturing processes are revolutionizing the market. Innovations such as automated systems and single-use technologies are improving efficiency and scalability, reducing production costs, and accelerating time-to-market. These advancements are crucial for meeting the rising demand for cell and gene therapies. Regulatory support and favorable policies are also driving market growth. Governments and regulatory bodies are streamlining approval processes and providing incentives for research and development, fostering innovation and investment in this sector. Moreover, collaborations between biotech companies and academic institutions are accelerating the development of novel therapies, expanding the market's potential. Finally, the increasing prevalence of chronic diseases and genetic disorders is fueling demand for cell and gene therapies. As awareness of these therapies grows, so does the need for reliable manufacturing services to ensure their availability and accessibility. This confluence of factors positions the market for sustained expansion and offers lucrative opportunities for stakeholders.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Allogeneic
    • 4.1.2 Autologous
    • 4.1.3 Viral Vectors
    • 4.1.4 Non-viral Vectors
    • 4.1.5 Plasmid DNA
    • 4.1.6 Cell Lines
    • 4.1.7 Gene Editing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Therapy Products
    • 4.2.2 Gene Therapy Products
    • 4.2.3 Viral Vector Products
    • 4.2.4 Non-viral Vector Products
    • 4.2.5 Plasmid DNA Products
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Process Development
    • 4.3.2 Analytical Testing
    • 4.3.3 Quality Control
    • 4.3.4 Regulatory Support
    • 4.3.5 Supply Chain Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 TALEN
    • 4.4.3 ZFN
    • 4.4.4 Lentiviral Vectors
    • 4.4.5 AAV Vectors
    • 4.4.6 Retroviral Vectors
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Reagents
    • 4.5.2 Media
    • 4.5.3 Buffers
    • 4.5.4 Serum-Free Media
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiovascular Diseases
    • 4.6.3 Neurological Disorders
    • 4.6.4 Rare Diseases
    • 4.6.5 Infectious Diseases
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
    • 4.7.3 Fill and Finish
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Biopharmaceutical Companies
    • 4.8.2 Research Institutes
    • 4.8.3 Contract Research Organizations
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Clinical
    • 4.9.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Process
      • 5.2.1.8 End User
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Process
      • 5.2.2.8 End User
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Process
      • 5.2.3.8 End User
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Process
      • 5.3.1.8 End User
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Process
      • 5.3.2.8 End User
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Process
      • 5.3.3.8 End User
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Process
      • 5.4.1.8 End User
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Process
      • 5.4.2.8 End User
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Process
      • 5.4.3.8 End User
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Process
      • 5.4.4.8 End User
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Process
      • 5.4.5.8 End User
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Process
      • 5.4.6.8 End User
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Process
      • 5.4.7.8 End User
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Process
      • 5.5.1.8 End User
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Process
      • 5.5.2.8 End User
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Process
      • 5.5.3.8 End User
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Process
      • 5.5.4.8 End User
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Process
      • 5.5.5.8 End User
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Process
      • 5.5.6.8 End User
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Process
      • 5.6.1.8 End User
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Process
      • 5.6.2.8 End User
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Process
      • 5.6.3.8 End User
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Process
      • 5.6.4.8 End User
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Process
      • 5.6.5.8 End User
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Wu Xi App Tec
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Lonza
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Catalent
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Sartorius
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Thermo Fisher Scientific
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Charles River Laboratories
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Parexel
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Pall Corporation
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Bio NTech
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Fujifilm Diosynth Biotechnologies
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Samsung Biologics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 AGC Biologics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Cognate Bio Services
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Oxford Biomedica
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Miltenyi Biotec
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Cell and Gene Therapy Catapult
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Center for Breakthrough Medicines
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vineti
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Bluebird Bio
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Orchard Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us